strong driven solid beat across product new growth driver incl even
biosimilar solid launch otezla weak like due disrupt
transit celgen guidanc look conserv neulasta
sensipar ex-u continu face pressur trim est still
stronger expect driven strong top-lin growth top-lin
annual guidanc histor conserv ep usual beat
henc comfort histor trend continu
especi much base busi better foot
part new growth drive includ otezla biosimilar even help trend
lower pt trim estim total rev partial
off-set lower opex new total product sale slightli
guidanc view neulasta sensipar ex-u epogen us
see pressur due biosimilar see growth driven new product cycl
off-set headwind
even biosimilar solid launch rais estim
even solid start quarter market japan quarter
us post strong sale q/q sale benefit
recent approv europ view street continu under-estim
futur sale potenti brand given unmet need rais global sale
estim
biosimilar franchis also grow nice mvasi kanjinti show strong
uptak post sale respect short time
quarter us market global franchis annual billion run rate
rais estim
neulasta soft q/q y/i biosimilar competit
unlik diminish despit onpro retain solid share onpro exit
market share brand see pressur entri sandoz ex-u sale
sensipar erod due gener entri henc continu project
soft brand
pleas see page report import disclosur
like fundament due diversifi product mix biolog franchis
durabl protect product innov pipelin tight control opex
aggress cash return sharehold see near-term risk enbrel sensipar
gener challeng new product launch includ aimovig biosimilar
provid new growth prospect legaci franchis declin opinion amgen
continu provid sustain growth navig turbul water
legaci franchis erod meantim tezepelumab earli stage oncolog pipelin
gain visibl shore confid long-term prospect
fda decis otezla scalp psoriasi
data otezla psoriasi mid
data nsclc
data
data tezepelumab asthma
data mm
data
data omecamtiv mecarbil
grow dividend consist stock
neulasta enbrel sensipar eros
less expect
aimovig biosimilar tezepelumab
tezepelumab success becom
revenu growth greater
pipelin contribut substanti
valu model
biosimilar launch exceed
neulasta rapid share loss sensipar
tezepelumab drug
aimovig slow
fail rais dividend pursu
success navig biosimilar competit legaci franchis
still contend patent challeng age brand nevertheless tight opex
control margin expans stock buyback new product launch ep growth
resili manag grow dividend annual major brand includ enbrel
sale neulasta denosumab franchis brand xgeva cancer
prolia osteoporosi sale aranesp/epogen like
tezepelumab asthma solid tumor earli stage oncolog pipelin
solid liquid tumor biosimilar franchis aimovig also provid attract
lot pipelin news expect make must stock
view robust pipelin mani milestones/data readout expect
make attract stock year
expect receiv fda decis otezla scalp psoriasi april
anticip data studi otezla mild-to-moder psoriasi mid
importantli anticip studi tezepelumab uncontrol sever asthma
late could drive attract return could unlock lucr franchis
recent conclud enrol pivot studi nsclc
brisk month data like support file initi data
monotherapi studi keytruda combo studi nsclc
expect compani also plan report initi data
monotherapi studi solid tumor
base anticip event rate data studi omecamtiv mercarbil
heart failur expect earlier prior estim
plan report data first-in-human dose escal data
studi cardiovascular diseas data
expect share outperform compani post upsid consensu revenu
ep expect anticip compani receiv credit
promis late stage pipelin product balanc year
cowen compani
cowen compani
amgen quarterli model growth us ex-u growth y/i erythropoietin enbrel growth us ex-u sale g-csf growth quarter-over-quart us ex-u us ex-u dmab growth us ex-u kyproli growth us ex-u us ex-u us ex-u us ex-u us ex-u growth probabl product sale growth revenu growth good sold margin margin product incom growth gaap growth share outstand cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
forecast sale product difficult outlook could alter
competit clinic develop failur reimburs chang new competit
could also impact sale estim pipelin product might fail develop
risk includ clinic develop regulatori price commerci challeng may
prevent financi forecast materi
